Cellectis (CLLS)

• Market cap: $366M
• 1 day: -1.88%
• 5 days: 11.96%
• 1 month: -17.42%
• 3 months: 37.22%
• 6 months: 141.72%
• Year to date: 101.66%
• 1 year: 84.34%
• 5 years: -79.71%
• 10 years: -89.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222